Stocks › CHRS

Coherus Oncology, Inc.

CHRS·Nasdaq·United States United States·USD
$0.37
-0.02 (-4.47%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CHRS
Coherus Oncology, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CHRSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of CHRS by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Shri ThanedarShri ThanedarHouse · D · MI CHRSCoherus Oncology, Inc. · Stock Sale
$15,001 - $50,000
Feb 9, 2023 Jan 23, 2023 Filing ↗

Whale Activity

Position changes in CHRS reported for 2026-09-30 by 163 institutional filers
Increased: 40New: 16Held: 30Decreased: 46Closed: 28No prior filing: 3
  • Increased40
  • New16
  • Held30
  • Decreased46
  • Closed28
  • No prior filing3
FilerSharesValueChange
Timothy G. Youngquist 2020 Irrevocable Trust13.1M$15.8Mheld
BlackRock, Inc.11.7M$14.2Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC5.6M$6.8Mdecreased
Samsara BioCapital, LLC3.4M$4.1Mdecreased
GEODE CAPITAL MANAGEMENT, LLC3.1M$3.8Mdecreased
Kohlberg Kravis Roberts & Co. L.P.3.0M$3.6Mheld
STATE STREET CORP2.4M$2.9Mincreased
CM Management, LLC2.1M$2.5Mheld
GOLDMAN SACHS GROUP INC2.0M$2.4Mincreased
C WorldWide Group Holding A/S1.9M$2.3Mheld
ADAR1 Capital Management, LLC1.9M$2.3Mincreased
Hudson Bay Capital Management LP1.7M$2.1Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by CHRS insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: 02025 Q12025 Q2: -100.0K2025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

799 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Satvat Ali J.Director Grant / award +30.0K $0.00 $0 Jun 5, 2026 Form 4 ↗
Karachun Rita ADirector Grant / award +30.0K $0.00 $0 Jun 5, 2026 Form 4 ↗
Newcomer Lee NisleyDirector Grant / award +30.0K $0.00 $0 Jun 5, 2026 Form 4 ↗
Ryan Michael LeeDirector Grant / award +30.0K $0.00 $0 Jun 5, 2026 Form 4 ↗
O'Donnell-Tormey JillDirector Grant / award +30.0K $0.00 $0 Jun 5, 2026 Form 4 ↗
Wahlstrom MatsDirector Grant / award +30.0K $0.00 $0 Jun 5, 2026 Form 4 ↗
Newton Charles W.Director Grant / award +30.0K $0.00 $0 Jun 5, 2026 Form 4 ↗
Lanfear Dennis MPresident & CEO · Director Grant / award +375.0K $0.00 $0 Jan 23, 2026 Form 4 ↗
McMichael Bryan JChief Financial Officer Grant / award +112.5K $0.00 $0 Jan 22, 2026 Form 4 ↗
McMichael Bryan JChief Financial Officer Tax withholding −1,715 $1.55 $3K Jan 20, 2026 Form 4 ↗
Lanfear Dennis MPresident & CEO · Director Tax withholding −11.8K $1.55 $18K Jan 20, 2026 Form 4 ↗
Wahlstrom MatsDirector Sale −100.0K $0.74 $74K May 23, 2025 Form 4 ↗
McMichael Bryan JChief Financial Officer Tax withholding −1,711 $1.39 $2K Jan 20, 2025 Form 4 ↗
Reider PaulChief Commercial Officer Tax withholding −4,858 $1.39 $7K Jan 20, 2025 Form 4 ↗
Lanfear Dennis MPresident & CEO · Director Tax withholding −11.8K $1.39 $16K Jan 20, 2025 Form 4 ↗
McMichael Bryan JChief Financial Officer Tax withholding −1,711 $1.57 $3K Jan 7, 2025 Form 4 ↗
Lanfear Dennis MPresident & CEO · Director Tax withholding −11.8K $1.66 $20K Jan 4, 2025 Form 4 ↗
Reider PaulChief Commercial Officer Tax withholding −2,277 $1.66 $4K Jan 4, 2025 Form 4 ↗
Reider PaulChief Commercial Officer Tax withholding −2,073 $1.61 $3K Dec 13, 2024 Form 4 ↗
Wahlstrom MatsDirector Gift +100.0K $0.00 $0 Feb 9, 2024 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding CHRS · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
4.0M$5.5M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
3.2M$4.5M0.01%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.9M$2.6M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.4M$2.0M0.01%Jul 31, 2026
Nomura Healthcare Fund
Delaware Group Equity Funds IV
900.0K$1.3M0.17%Jun 30, 2026
BlackRock Advantage Small Cap Core Fund
BlackRock Funds
927.8K$1.3M0.02%Aug 31, 2026
iShares Russell 2000 Value ETF
iShares Trust
741.5K$1.0M0.01%Jun 30, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
763.0K$1.0M0.00%Aug 31, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
747.1K$1.0M0.01%Aug 31, 2026
Schwab U.S. Small-Cap ETF
SCHWAB STRATEGIC TRUST
702.7K$949K0.00%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list CHRS's shares (CUSIP 19249H103), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • BlackRock, Inc.SCHEDULE 13G · passive (13G) · 8.9M shares5.8%
    Jul 27, 2026 · ↗
  • Timothy G. Youngquist 2020 Irrevocable TrustSCHEDULE 13G/A · passive (13G) · 12.8M shares8.3%
    May 15, 2026 · ↗
  • Timothy G. Youngquist 2020 Irrevocable TrustSCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    May 11, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Coherus Oncology, Inc. as client

No lobbying filings found naming Coherus Oncology, Inc. as the client.

Government Contracts

Federal awards to Coherus Oncology, Inc. · USAspending

No federal contract awards found for Coherus Oncology, Inc..

U.S. Patents

Recent USPTO applications naming Coherus Oncology, Inc.

No USPTO patent applications found for Coherus Oncology, Inc..

Annual Financials

From CHRS's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$181.1M-$199.7M-$203.2M-$256.9M-$263.9M
Net income$168.0M$28.5M-$237.9M-$291.8M-$287.1M
Diluted EPS$1.43$0.25-$2.53-$3.76-$3.81
Operating cash flow-$138.5M-$20.4M-$174.9M-$241.1M-$37.4M
Cash and equivalents$88.9M$126.0M$102.9M$63.5M$417.2M
Total assets$258.3M$448.5M$629.6M$480.8M$679.3M
Total liabilities$197.3M$580.5M$823.0M$618.3M$581.6M
Shareholders' equity$61.0M-$132.0M-$193.4M-$137.4M$97.7M

As Coherus Oncology, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 9, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in CHRS's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsOct 29, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 17, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 1.02, 2.03, 9.01Material agreement · Termination of agreement · Direct financial obligationAug 17, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
    EDGAR ↗
  • 8-K · Items 4.01, 9.01Change in auditorJun 15, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 1, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
    EDGAR ↗

About Coherus Oncology, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersREDWOOD CITY, CA
IncorporatedDE
Former namesCoherus BioSciences, Inc., BioGenerics, Inc.